Anuh Pharma Ltd
Anuh Pharma Ltd Q4 FY26 Results & Presentation Highlights: Revenue, Margins & Order Book
Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Anuh Pharma Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q4 FY26 Revenue: Rs. Quarterly EBITDA (Q4 FY26): Rs.
From Anuh Pharma Ltd's Q4 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY26 Revenue: Rs. 202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14)
- FY26 Revenue: Rs. 776 Cr., a 15.66% increase year-on-year (Pages 7 and 14)
- Q4 FY26 Total Production: 426 MT, slight change (-0.04%) quarter-on-quarter (Page 6)
- FY26 Total Production: 1733 MT, a 24.99% increase year-on-year (Page 6)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Anuh Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹202 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q4 FY26 inv
- Remus Pharmaceuticals Ltd (Q4 FY26)
Quarterly Revenue (H2-FY26):** INR 4,534 Mn, up 30.4% YoY from INR 3,478 Mn in H2-FY25 . Key investor presentation takeaways from Remus Pharmaceuticals Ltd's Q4
- Lincoln Pharmaceuticals Ltd (Q4 FY26)
EBITDA: ₹26 crore, a 3% year-on-year increase . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how i
- Kopran Ltd (Q4 FY26)
6,166 Lakhs increase (~35.8% growth) . Key investor presentation takeaways from Kopran Ltd's Q4 FY26 investor presentation — and how it ranks against sector pee
Frequently Asked Questions
What were Anuh Pharma Ltd Q4 FY26 results?
Q4 FY26 Revenue: Rs. Quarterly EBITDA (Q4 FY26): Rs.
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
The presentation does not explicitly detail specific capex amounts, new plant/project names, or exact timelines for capacity expansion.
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.